ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

About ASN

Ronald D. Perrone, MD, FASN, BRCU Faculty

ASN Biography

Ronald D. Perrone, MD, FASN, has had a long-standing and wide-ranging interest in ADPKD. He has participated in all of the major clinical trials in ADPKD, serving as the Boston site Principal Investigator and member of the Steering Committees for the HALT PKD study, the TEMPO 3/4 and REPRISE trials of tolvaptan in ADPKD, the TAME-PKD study of metformin, and the Venglustat STAGED-PKD study. He also serves as Boston site PI for the Tesevatinib and Bardoxolone (Falcon) studies.

Dr. Perrone has been a member of the Scientific Advisory Committee of the U.S. Polycystic Kidney Disease Foundation from 1999 to 2017 (Chairman from 2006-2010). He initiated and co-led the PKD Outcomes Consortium and has been the principal individual involved in bringing together the contributors from academia, pharma, NIH, FDA, EMA, CDISC, and C-Path. Total kidney volume has been approved as a prognostic biomarker by both the FDA and the EMA.